IHL

cover
Incannex召开Pre-IND会议获取美国FDA的药物开发计划的反馈

临床阶段药物开发公司Incannex Healthcare Limited(ASX:IHL)已获得与美国食品和药物管理局(FDA)进行PRE-IND会议的资格,会议围绕其候选药IHL-675A在急性呼吸窘迫综合征(ARDS)和败血症相关急性呼吸窘迫综合征(SAARDS)中的预防效果。

cover
Incannex IHL-675A has outperformed existing treatment for arthritis and initiated 6th research program

Incannex Healthcare Limited (ASX: IHL), a clinical-stage pharmaceutical development company, has resumed trading following the announcement of its sixth research program as more positive pre-clinical study data showed that IHL-675A, one of IHL’s drug candidates, has stronger anti-inflammatory properties in the treatment of rheumatoid arthritis than an existing medication called Plaquenil.